Skip to main content
OpenTrials
Completed

NCT Number: NCT05553691

SPL026 With or Without SSRIs in Participants With MDD

The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Mac Clinical Research, Manchester, Greater Manchester, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • MDD diagnosis
  • Previously tried at least one approved method of treatment for their depression
  • No monoamine oxidase-inhibitor class antidepressants for at least 3 months
  • Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, laboratory tests of blood and urine
  • No psychedelic drug use in the 6 months before dosing until the end of the study
  • Willing to follow the contraception requirements of the trial
  • Willing to be contacted by email and video call, and have online access
  • Able to give fully informed written consent
  • Test Cohort only: currently on a stable dose of an unspecified single SSRI alone and not in combination with any other psychiatric medications, for at least 6 weeks prior to Screening with no intention of making any changes
  • Control Cohort only: no antidepressant medication for 6 months before dosing

Exclusion criteria

  • Substance use disorder
  • Current or clinically relevant history of a psychotic disorder, or first-degree relatives with a clinically relevant history of a psychotic disorder
  • Significant history of mania
  • Significant risk of suicide
  • Clinically relevant abnormal findings at the screening assessment
  • Blood pressure, heart rate, or QTcF outside the acceptable ranges
  • Acute or chronic illness (other than MDD) or infection
  • Clinically relevant abnormal medical history or concurrent medical condition (other than MDD)
  • Use of any serotonergic psychedelics within 6 months prior to dosing
  • Patients of child-bearing potential who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception
  • History of a severe adverse reaction to any drug or sensitivity to serotonergic psychedelic drugs
  • Use of over-the-counter or prescribed medication (excluding oral contraceptives, hormone replacement therapy and SSRIs [Test Cohort only]) within previous 28 day before dose of trial medication; or paracetamol or ibuprofen within 4 hours prior to dosing

Treatment and study plan

SPL026

Drug

Intravenous

Other names: N,N-dimethyltryptamine, DMT

Primary outcomes

  1. Safety & tolerability: Adverse Events

    Time frame: Screening to End-of-Study Follow-up (Day 29)

    Adverse events (AEs)

  2. Safety & tolerability: Lab biochemistry

    Time frame: Screening, Day -1 and Day 1

    Values of potential clinical importance

  3. Safety & tolerability: Vital signs - Heart Rate

    Time frame: Screening to Day 2

    Heart rate

  4. Safety & tolerability: Vital signs - Blood pressure

    Time frame: Screening to Day 2

    Blood pressure

  5. Safety & tolerability: Vital signs - Temperature

    Time frame: Screening to Day 2

    Temperature

  6. Safety & tolerability: Electrocardiogram

    Time frame: Screening to Day 2

    QTcX intervals

  7. Safety & tolerability: Suicidal Ideation

    Time frame: Screening to End-of-Study Follow-up (Day 29)

    Columbia-Suicide Severity Rating Scale

Secondary outcomes

  1. Evaluation of plasma levels of DMT

    Time frame: 2, 5, 7, 10, 11, 13, 15, 30, 60, 120, 240 minutes post-dose

    Pharmacokinetic parameter calculation in the Test Cohort compared to the Control Cohort

  2. Mystical Experience Questionnaire (MEQ)

    Time frame: Day 1 (dosing day)

    MEQ in the Test Cohort compared to the Control Cohort

  3. Challenging Experience Questionnaire (CEQ)

    Time frame: Day 1 (dosing day)

    CEQ in the Test Cohort compared to the Control Cohort

  4. Ruminative Responses Scale (RRS)

    Time frame: Day -1 and Day 29

    RRS in the Test Cohort compared to the Control Cohort

  5. Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)

    Time frame: Day -1, Day 15 and Day 29

    WEMWBS in the Test Cohort compared to the Control Cohort

Other outcomes

  1. Exploratory efficacy: Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: Day -1, Day 8, Day 15 and Day 29

    MADRS in the Test Cohort compared to the Control Cohort

Sponsors and collaborators

Lead sponsor

Small Pharma Ltd

Industry

Registry information

Official study title

An Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics & Exploratory Efficacy of Intravenous SPL026 Drug Product (DMT Fumarate) Alone or in Combination With SSRIs in Patients With Major Depressive Disorder

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Sep 23, 2022
Registry last updated
Jun 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.